| ADVM |
ADVERUM BIOTECHNOLOGIES, INC. |
Common Stock, $0.0001 par value per share |
19.4% |
$17.5M |
$12.9M |
4.29M |
+280% |
Frazier Life Sciences Public Fund, L.P. |
Nov 25, 2025 |
| MBX |
MBX BIOSCIENCES, INC. |
Common Stock, $0.0001 par value per share |
11.7% |
$72.6M |
$9.26M |
5.22M |
+14.6% |
Patrick J. Heron |
Sep 26, 2025 |
| XLO |
Xilio Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
9.9% |
$5.62M |
$1.65M |
8.14M |
+41.7% |
Frazier Life Sciences Public Fund, L.P. |
Jun 30, 2025 |
| PHAT |
PHATHOM PHARMACEUTICALS, INC. |
Common Stock, $0.0001 par value per share |
8.6% |
$70.4M |
|
5.99M |
0% |
James N. Topper |
Nov 1, 2025 |
| NAMS |
NEWAMSTERDAM PHARMA COMPANY N.V. |
Ordinary Shares, nominal value EUR0.12 per share |
7.7% |
$245M |
$36.9M |
8.62M |
+17.7% |
Frazier Life Sciences Public Fund, L.P. |
Nov 1, 2025 |
| MAZE |
Maze Therapeutics, Inc. |
Common Stock - par value $0.001 per share |
7.7% |
$46.5M |
-$15.2M |
3.35M |
-24.7% |
Frazier Life Sciences Public Fund, L.P. |
Jun 30, 2025 |
| TRVI |
Trevi Therapeutics, Inc. |
Common Stock, $0.001 par value per share |
7% |
$77.8M |
-$16M |
8.51M |
-17.1% |
Frazier Life Sciences Public Fund, L.P. |
Sep 30, 2025 |
| KALV |
KALVISTA PHARMACEUTICALS, INC. |
Common Stock, $0.001 par value per share |
6.9% |
$42.2M |
$13M |
3.47M |
+44.4% |
Frazier Life Sciences Public Fund, L.P. |
Nov 1, 2025 |
| LXEO |
Lexeo Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
5.7% |
$14.5M |
|
3.07M |
|
Frazier Life Sciences Public Fund, L.P. |
Jun 30, 2025 |
| ERAS |
Erasca, Inc. |
Common Stock, $0.0001 par value per share |
5.3% |
$23.8M |
-$11.9M |
15M |
-33.4% |
Frazier Life Sciences Public Fund, L.P. |
Jun 30, 2025 |
| AURA |
Aura Biosciences, Inc. |
Common Stock, $0.00001 par value per share |
5% |
$20.2M |
-$20.8M |
3.11M |
-50.7% |
Frazier Life Sciences Public Fund, L.P. |
Jun 30, 2025 |
| PVLA |
Palvella Therapeutics, Inc. |
Common Stock, $0.001 par value per share |
4.9% |
$28M |
-$7.41M |
546K |
-20.9% |
Frazier Life Sciences Public Fund, L.P. |
Jun 30, 2025 |
| JBIO |
JADE BIOSCIENCES, INC. |
Common Stock, $0.0001 par value per share |
4.2% |
$11.9M |
$379K |
1.38M |
+3.28% |
Frazier Life Sciences Public Fund, L.P. |
Sep 30, 2025 |
| MREO |
Mereo BioPharma Group plc |
Ordinary Shares, nominal value EURO0.003 per share, represented by American Depository Shares |
4.1% |
$56.8M |
-$13.9M |
32.4M |
-19.6% |
Frazier Life Sciences Public Fund, L.P. |
Jun 30, 2025 |
| SVRA |
Savara Inc. |
Common Stock, par value $0.001 per share |
3.9% |
$22.2M |
-$15.5M |
6.75M |
-41.2% |
Frazier Life Sciences Public Fund, L.P. |
Jun 30, 2025 |
| IRON |
DISC MEDICINE, INC. |
Common Stock, par value $0.0001 per share |
3% |
$61.3M |
|
1.03M |
|
Frazier Life Sciences Public Fund, L.P. |
Jun 30, 2025 |
| MGNX |
MACROGENICS, INC. |
Common Stock, par value $0.01 per share |
2.5% |
$2.23M |
|
1.55M |
|
Frazier Life Sciences Public Fund, L.P. |
Jun 30, 2025 |
| ORIC |
ORIC Pharmaceuticals, Inc. |
Common Stock, $0.0001 par value per share |
2% |
$6.94M |
|
1.41M |
|
James N. Topper |
Mar 31, 2025 |
| ELDN |
Eledon Pharmaceuticals, Inc. |
Common Stock |
2% |
$3.33M |
|
1.18M |
|
James N. Topper |
Dec 31, 2024 |
| ANAB |
AnaptysBio, Inc. |
Common Stock |
0.5% |
|
|
|
|
Frazier Life Sciences Public Fund, L.P. |
Jan 31, 2025 |
| ANTX |
AN2 THERAPEUTICS, INC. |
Common Stock |
0% |
$0 |
|
0 |
|
Frazier Life Sciences Public Fund, L.P. |
Dec 31, 2024 |
| PBYI |
Puma Biotechnology, Inc. |
Common Stock |
0% |
$0 |
|
0 |
|
Frazier Life Sciences Public Fund, L.P. |
Dec 31, 2024 |
| HLVX |
HILLEVAX, INC. |
Common Stock, par value $0.0001 per share |
0% |
$0 |
|
0 |
|
Frazier Life Sciences Public Fund, L.P. |
Sep 17, 2025 |
| ELEV |
Elevation Oncology, Inc. |
Common stock, par value $0.0001 per share |
0% |
$0 |
|
0 |
|
Frazier Life Sciences Public Fund, L.P. |
Jul 23, 2025 |